Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 4, 2011, Pages 738-747

  Dienava Verdoold, I ^a   Boon Spijker, M G ^a   De Groot, P G ^b   Brinkman, H J M ^a   Voorberg, J ^a   Mertens, K ^a,c   Derksen, R H W M ^b   De Laat, B ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiphospholipid syndrome; Beta2 glycoprotein 1; Lupus anticoagulants; MAb; Phage display

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CD19 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; P1 117 ANTIBODY; P1 190 ANTIBODY; P2 162 ANTIBODY; P2 6 ANTIBODY; PHOSPHOLIPID ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THROMBIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTICOAGULATION; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; B LYMPHOCYTE; CASE REPORT; CLONING VECTOR; DIMERIZATION; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; NUCLEOTIDE SEQUENCE; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; THROMBOSIS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUPUS COAGULATION INHIBITOR; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79953320606     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04212.x     Document Type: Article

References (40)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Chukwuocha RU, Zhu M, Cho CS, Visvanathan S, Hwang KK, Rahman A, Chen PP. Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. Mol Immunol 2002; 39: 299-311.
3. Farmer-Boatwright MK, Roubey RA. Venous thrombosis in the antiphospholipid syndrome. Arterioscler Thromb Vasc Biol 2009; 29: 321-5.
4. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 2-6.
5. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoproteinI (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
6. Iverson GM, Reddel S, Victoria EJ, Cockerill KA, Wang YX, Marti-Renom MA, Sali A, Marquis DM, Krilis SA, Linnik MD. Use of single point mutations in domain I of beta2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-103.
7. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5.
8. Ioannou Y, Rahman A. Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus 2010; 19: 400-5.
9. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-24.
10. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, Derksen RH, Meijers JC, de Groot PG. Beta2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-43.
11. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P. Adhesion mechanism of human beta2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
12. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-39.
13. Willems GM, Janssen MP, Pelsers MM, Comfurius P, Galli M, Zwaal RF, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
14. Pierangeli SS, Chen PP, Gonzalez EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13: 366-75.
15. Del Papa N, Sheng YH, Raschi E, Kandiah DA, Tincani A, Khamashta MA, Atsumi T, Hughes GRV, Ichikawa K, Koike T, Balestrieri G, Krilis SA, Meroni PL. Human beta2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta2-glycoprotein I antibodies. J Immunol 1998; 160: 5572-8.
16. Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Moal V, Sanmarco M, Sampol J. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-73.
17. Wolberg AS, Roubey RA. Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res 2004; 114: 391-6.
18. Pennings MTT, Derksen RHWM, van Lummel M, Adelmeijer J, VanHoorelbeke K, Urbanus RT, Lisman T, De Groot PG. Platelet adhesion to dimeric beta2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 2007; 5: 369-77.
19. Safa O, Esmon CT, Esmon NL. Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-beta2-glycoprotein I monoclonal antibodies. Blood 2005; 106: 1629-35.
20. Rand J, Wu X. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 649-55.
21. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86: 83-91.
22. Lai CJ, Rauch J, Cho CS, Zhao Y, Chukwuocha RU, Chen PP. Immunological and molecular analysis of three monoclonal lupus anticoagulant antibodies from a patient with systemic lupus erythematosus. J Autoimmun 1998; 11: 39-51.
23. Pierangeli SS, Liu X, Espinola R, Olee T, Zhu M, Harris NE, Chen PP. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84: 388-95.
24. Chukwuocha RU, Hsiao ET, Shaw P, Witztum JL, Chen PP. Isolation, characterization and sequence analysis of five IgG monoclonal anti-beta2-glycoprotein-1 and anti-prothrombin antigen-binding fragments generated by phage display. J Immunol 1999; 163: 4604-11.
25. Languren M, Becerril B, Cabral AR, Fernandez-Altuna LE, Pascual V, Hernandez-Ramirez DF, Cabiedes J. Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome. J Autoimmun 2006; 26: 57-65.
26. Prinz N, Hauser F, Lorenz M, Lackner KJ, von Landenberg P. Structural and functional characterization of a human IgG monoclonal antiphospholipid antibody. Immunobiology 2011; 216: 145-51.
27. Azzazy HME, Highsmith WE. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002; 35: 425-45.
28. Luken BM, Kaijen PHP, Turenhout EAM, Kremer Hovinga JA, van Mourik JA, Fijnheer R, Voorberg J. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 2355-64.
29. Pos W, Luken BM, Kremer Hovinga JA, Turenhout EAM, Scheiflinger F, Dong JF, Fijnheer R, Voorberg J. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 421-8.
30. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJH, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-8.
31. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 1985; 77: 305-19.
32. van Veen JJ, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. Thromb Res 2009; 123: 895-901.
33. Sheng Y, Kandiah DA, Krilis SA. Anti-beta2-glycoprotein I autoantibodies from patients with the 'antiphospholipid' syndrome bind to beta2-glycoprotein I with low affinity: dimerization of beta2-glycoprotein I induces a significant increase in anti-beta2-glycoprotein I antibody affinity. J Immunol 1998; 161: 2038-43.
34. Cabiedes J, Cabral AR. Anti-beta2-glycoprotein-I antibodies in scFv format. Autoimmun Rev 2005; 4: 289-95.
35. Blank M, Waisman A, Mozes E, Koike T, Shoenfeld Y. Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome. Int Immunol 1999; 11: 1917-26.
36. Giles IP, Haley JD, Nagl S, Isenberg DA, Latchman DS, Rahman A. A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. Semin Arthritis Rheum 2003; 32: 246-65.
37. Lutters BCH, Meijers JCM, Derksen RH, Arnout J, de Groot PG. Dimers of beta2-glycoprotein I mimic the in vitro effects of beta2-glycoprotein I-anti-beta2-glycoprotein I antibody complexes. J Biol Chem 2001; 276: 3060-7.
38. Kondo A, Miyamoto T, Yonekawa O, Giessing AM, Osterlund EC, Jensen ON. Glycopeptide profiling of beta2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome. J Proteomics 2009; 73: 123-33.
39. van den Brink EN, Turenhout EAM, Bovenschen N, Heijnen BGAD, Mertens K, Peters M, Voorberg J. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII. Blood 2001; 97: 966-72.
40. van den Brink EN, Bril WS, Turenhout EAM, Zuurveld M, Bovenschen N, Peters M, Yee TT, Mertens K, Lewis DA, Ortel TL, Lollar P, Scandella D, Voorberg J. Two classes of germline genes both derived from the VH1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. Blood 2002; 99: 2828-34.